Omeros (OMER) Expected to Announce Earnings on Monday

Omeros (NASDAQ:OMER) is anticipated to post its quarterly earnings results after the market closes on Monday, March 24th. Analysts expect Omeros to post earnings of ($0.69) per share for the quarter.

Omeros Stock Performance

NASDAQ OMER opened at $9.10 on Friday. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60. The stock has a market cap of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03. The firm’s 50 day moving average price is $8.70 and its two-hundred day moving average price is $7.32.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday. D. Boral Capital reiterated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Friday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.